News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Here's Why Investors Weren't Excited About Biogen (BIIB)'s New CEO



12/20/2016 6:56:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Biogen shares dropped as much as 4.6% on news of his appointment Monday.

Biogen, the U.S. drug maker focused on neurological, autoimmune and rare diseases, said on Monday it had appointed its chief commercial officer, Michel Vounatsos, as chief executive officer, ending a five-month search.

Biogen shares fell on the news of his appointment, which is effective as of Jan. 6. Vounatsos succeeds CEO George Scangos, who announced last July he would retire after leading the company since 2010.

Read at Fortune


comments powered by Disqus
Fortune
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES